ArticleScientific reports2025
T817MA protects against inflammation and pyroptosis in response to brain ischemia via activating Sirt1 signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebral Ischemia-Reperfusion Injury: Unraveling the Mitophagy-Oxidative Stress Axis for Neuroprotective Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke remains a leading cause of death and disability worldwide, yet effective neuroprotective therapies are lacking. Neuroinflammation and pyroptosis, a lytic and inflammatory form of programmed cell death, exacerbate secondary brain injury post-ischemia. This study investigated the neuroprotective effects of T817MA, a neurotrophic agent, in a rat model of transient middle cerebral artery occlusion (MCAO), focusing on its anti-pyroptotic mechanisms via Sirtuin1 (Sirt1) signaling. Animals were pretreated orally with T817MA at 30 mg/kg for 20 days, and brain edema was evaluated by brain water content. Neurological dysfunction was determined by modified neurological severity score (mNSS) and rotating pole test, and neuroinflammatory markers were assayed by immunostaining. Pyroptosis and potential molecular mechanisms were detected by measuring related proteins using western blot. T817MA treated rats exhibited reduced brain edema, improved neurological recovery, and attenuated motor-coordination deficits post-MCAO. T817MA suppressed neuroinflammation, evidenced by decreased activation of microglia (ionized calcium binding adapter molecule 1, Iba-1) and astrocytes (glial fibrillary acidic protein, GFAP). Mechanistically, T817MA inhibited caspase-1 cleavage, IL-1β release, and Gasdermin D (GSDMD)-mediated pyroptosis in neurons. Notably, T817MA prolonged Sirt1 activation up to 48 h post-ischemia, while Sirt1 inhibition with sirtinol reversed its protective effects on brain edema, caspase-1 activation, and IL-1β levels. These findings demonstrate that T817MA mitigates ischemic brain injury by suppressing neuroinflammation and pyroptosis through Sirt1-dependent pathways, highlighting its potential as a therapeutic candidate for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.